Pink SheetA single-arm study cannot provide interpretable results supporting promotional claims for progression-free survival or overall survival, the US Food and Drug Administration said in an advertising and
ScripAlnylam Pharmaceuticals’ Amvuttra (vitrisiran) will tap a substantially larger commercial opportunity with its US Food and Drug Administration approval for the treatment of ATTR with cardiomyopathy, b
In VivoA key indicator of the strength of the biopharma industry is the health of new company creation. By reviewing Series A financing announced in 2024 as a proxy, In Vivo once again takes measurement of
ScripOne key indicator of the health of the biopharma industry is the rate of new company creation, and a new Evaluate analysis, using series A financings as a proxy shows that 2024 saw an encouraging up